Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421044 · ClinicalTrials.gov registry record · Phase 1
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
A Phase 1 study of Tumors and Advanced Malignancies, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 3
- Study locations
NCT00421044 is a Phase 1 study of Tumors and Advanced Malignancies that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants, below the 199-participant average among 20 other Tumors trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00421044, a Phase 1 study of Tumors and Advanced Malignancies, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
Conditions Studied
Interventions
- DRUG Patupilone/EPO906
Study Locations (3)
Texas
- Institute for Drug Development Cancer Therapy & Research Center/The University of Texas Health Science Center - San Antonio
- South Texas Accelerated Research Therapeutics - San Antonio
California
- University of California San Diego/Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421044
The ClinicalTrials.gov registry entry for NCT00421044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 20 other Tumors trials with a reported enrollment target (93% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Patupilone/EPO906 is the first listed.
NCT00421044 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, California.
Frequently Asked Questions
What is clinical trial NCT00421044 about?
NCT00421044 is a clinical study titled "A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function". Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
What is the current status of trial NCT00421044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-05.
What conditions does trial NCT00421044 study?
This clinical trial studies the following conditions: Tumors, Advanced Malignancies.
What interventions are being tested in trial NCT00421044?
The interventions under investigation include: Patupilone/EPO906 (DRUG).
Who is sponsoring clinical trial NCT00421044?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00421044 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.